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In the last years, dendritic cells (DC) have been evaluated for antitumor vaccination. AlthoughDC-based vaccines have raised great
expectations, their clinical translation has been largely disappointing. For these results, several explanations have been proposed.
In particular, the concomitant expression by DCs of tolerogenic pathways, such as the immunosuppressive agent indoleamine 2,3-
dioxygenase-1 (IDO1), has been demonstrated.The aim of this study is to evaluate both the stimulatory and the tolerogenic feature
of monocyte-derived DCs (Mo-DCs) after maturation with PGE
2
. In particular, the role of IDO1 expression in PGE
2
-maturedMo-
DCs has been addressed. Here we show that PGE
2
, which is required for full maturation of DCs, is onemediator of DC tolerance by
enhancing IDO1. PGE
2
-mediated expression of IDO1 results in the production of kynurenine, in the generation of Tregs, and in the
inhibition of either the allogeneic or the autologous antigen-specific stimulatory capacity ofDCs.Whenpulsedwith leukemic lysates
and matured with PGE
2
, DCs are impaired in the induction of IFN-𝛾 secreting CD4+ and CD8+ T cells due to IDO1 upregulation.
Moreover, the inhibition of IDO1 enhances the antileukemic response. Overall, these results point toward the use of IDO1 inhibitors
to enhance the vaccination capacity of DCs, matured with PGE
2
.
1. Introduction
Indoleamine 2,3-dioxygenase-1 (IDO1) is an immunoregula-
tory enzyme that catalyzes the first and rate-limiting step of
tryptophan metabolism along the kynurenine [1]. Its activity
is blocked by 1 methyl-tryptophan (1-MT) and, preferentially,
by the L-isoform (1-MT-L) [2]. Tryptophan degradation and
kynurenine starvation result in the inhibition of T-cell activa-
tion, proliferation and survival [3, 4], and in the expansion of
regulatory T cells (Tregs) [5, 6]. The immunosuppressive and
tolerogenic role of IDO1 has been observed during maternal
tolerance toward the allogeneic fetus [7], regulation of auto-
immune disorders [8, 9], and suppression of transplant rejec-
tion [10] and in tumor escape [11–15].
Because of their natural features, dendritic cells (DCs)
are currently used as cellular vaccines against tumors [16]. In
peripheral blood, DCs are a rare population, but the devel-
opment of protocols to in vitro differentiate blood mono-
cytes into DCs (Mo-DCs) triggered the possibility of DC-
based immunotherapies [17]. However, DC-based vaccines
have demonstrated less clinical efficacy than anticipated.
To explain such dismal clinical results, several mechanisms
have been proposed. One potential key mechanism is the
expression of IDO1 by Mo-DCs. Indeed, Mo-DCs upregulate
IDO1 expression upon in vitromaturation with the standard
cytokine cocktail containing TNF-𝛼, IL-1𝛽, IL-6, and PGE
2
,
used in clinical protocols [18]. It has been shown that PGE
2
is necessary for the upregulation of CCR7 and metallo-
proteinase 9 (MMP-9) on DCs and for their consequent
migration into lymph nodes [19]. However, PGE
2
is one of the
prominent inducers of IDO1 expression [20]. It has been
shown that PGE
2
-mediated IDO1 upregulation in DCs does
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not impair their capacity of antigen presenting cell [21].
However, IDO1-expressing DCs attract or induce regulatory
Foxp3+ T cells and the presence of those cells at the site of
DC injection suggests possible immunoregulatory effects of
IDO1-expressing DCs [22]. Therefore, to improve DC-based
vaccine therapy, much attention has to be paid to IDO1
complex modulation by cytokine stimulation of DCs.
Here, we characterize IDO1 expression in human Mo-
DCsmatured in presence of PGE
2
, in order to test the efficacy
of high IDO1-expressing DCs in eliciting an antileukemic
response. We found that, combining PGE
2
with 1-MT-L, it is
possible to obtain fully mature Mo-DCs that weakly induce
Tregs and that elicit IFN-𝛾 release by T cells stimulated with
acute myeloid leukemia (AML) antigens.
2. Materials and Methods
2.1. Blood Samples. Cells were obtained from healthy donor
buffy coats or from peripheral blood of AML patients
who achieved complete remission (CR). PBMC were sep-
arated by density gradient centrifugation (Ficoll-Hypaque;
Amersham Bioscience, Piscataway, NJ). Cells were cul-
tured in RPMI 1640 medium (Lonza, Milan, Italy) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS)
(Gibco-Invitrogen, Carlsbad, CA, USA), 2mM L-glutamine,
100U/mL penicillin, and 100 𝜇g/mL streptomycin (MP Bio-
medicals, Verona, Italy) at 37∘C in 5% CO
2
. CD14+, CD3+,
and CD4+CD25+ cells were purified by magnetic separa-
tion column (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to manufacturer’s instructions.
2.2. DC Generation. Monocyte-derived DCs (Mo-DC) were
generated by a 5-day culture of CD14+ cells in complete
medium supplemented with 50 ng/mL granulocyte-macro-
phage colony-stimulation factor (GM-CSF) (Endogen,
Woburn, MA) and 800U/mL IL-4 (Endogen), at 37∘C in 5%
CO
2
[23]. For maturation, day 5 Mo-DCs were cultured with
GM-CSF and IL-4 and incubated for 48 hours in presence
of (a) complete medium, (b) 1 𝜇g/mL CD40L (Biolegend,
San Diego, CA), (c) 1 𝜇g/mL LPS (Sigma-Aldrich, St. Louise,
MO), (d) 1 𝜇g/mL LPS with 100U/mL IFN-𝛾 (Endogen), (e)
a cocktail of cytokine made of 10 ng/mL TNF-𝛼 (Endogen),
10 ng/mL IL-6 (Endogen), 10 ng/mL IL-1𝛽 (Endogen), with
or without 1 𝜇g/mL PGE
2
(Endogen).
2.3. IDO1 Expression. Total RNA was reverse transcribed in
20𝜇L using Promega Improm II kit and random hexamers
(Promega Corporation, Madison, WI, USA). Quantitative
real-time PCR (qRT-PCR) was performed using ABI-PRISM
7900 SequenceDetection System (Applied Biosystems, Foster
City, CA). qRT-PCR data were analyzed using the 2−ΔΔCt
method. The relative level of a specific mRNA for IDO1
was calculated by subtracting Ct values of the control gene
(GAPDH) from the Ct values of IDO1. Universal human
RNA (Stratagene, Agilent Technologies, Santa Clara, CA)was
used as reference and taken as value of 1, IDO1 Assay ID
Hs00158027 m1, GAPDH Assay ID Hs00266705 g1.
2.4. DC Immunophenotype. Dual-color immunofluores-
cence was performed using the following panel of mAbs: PE-
or FITC-conjugated anti-human HLA-DR (clone L242, BD
Pharmingen); PE- or FITC-conjugated anti-human CD1a
(clone HI149, Biolegend); PE- or FITC-conjugated anti-
human CD86 (clone IT2.2, Biolegend); PE-conjugated anti-
human CD80 (clone 2D10, Biolegend); PE- or FITC-conju-
gated anti-human CD14 (clone HCD14, Biolegend); FITC-
conjugated anti-human CD83 (clone HB15e, Biolegend);
FITC-conjugated anti-human CD40 (clone HB14, Bioleg-
end); PE-conjugated anti-human CCR7 (clone 150503,
BD Pharmingen). Negative controls were isotype-matched
irrelevant mAbs (BD Pharmingen, Biolegend). Cells were
analyzed by using FACScan equipment or C6 Accuri
equipment (Becton Dickinson). A minimum of 10,000
events was collected in list mode on FACScan software.
2.5. EnzymeActivity of IDO1. Theamount of L-kynurenine in
culture supernatants was measured with a spectrophotomet-
ric analysis [24]. Briefly, Mo-DCs were washed, resuspended
in Hanks buffer supplemented with 500𝜇M L-tryptophan
(Sigma-Aldrich), and incubated. Supernatants were har-
vested after 4 h and mixed with 30% trichloroacetic acid
(2 : 1), vortexed, and centrifugated at 8000 g for 5min. Sub-
sequently, this solution was added to Ehrlich’s reagent (1 : 1,
Sigma-Aldrich) in a 96-well plate. Triplicate samples were
run against a standard curve of defined kynurenine con-
centrations (0–100𝜇M; Sigma-Aldrich). Optical density was
measured at 490 nm, using aMultiskan EXmicroplate reader
(Thermo Electron Corporation, Vantaa, Finland).
2.6. Allogeneic andAutologous T-Cell Proliferation. Irradiated
(3000 cGy) Mo-DCs were incubated for 5 days with CFSE-
labeled CD3+ T cells (1 : 10), with or without 1-MT-L (1mM,
Sigma-Aldrich). For autologous mixed leukocyte reaction
(MLR) immature Mo-DCs were previously pulsed for 24 h
with tetanus toxin (1 𝜇g/mL; Sigma-Aldrich), then washed,
and matured. At the end of the culture time, cultures were
analyzed using BD FACSCanto II equipment (BD Bio-
sciences).
2.7. Induction of Allogeneic and Autologous T
𝑟𝑒𝑔𝑠
by Mo-
DCs. Mo-DCs were cultured with CD3+ T cells (1 : 50) for 5
days with or without 1-MT-L (1mM). At the end of culture
time, cells (1 × 105 cells/100 𝜇L) were incubated with FITC-
conjugated anti-human CD4 (clone RPA-T4) and APC-
conjugated anti-human CD25 (clone BC96, Biolegend) in
the dark for 20min at 4∘C and then for 30min at room
temperature with PE-conjugated anti-human Foxp3 (clone
206D), after 20min of fixation and 15min of permeabi-
lization. Samples were analysed using BD FACSCanto II
equipment (BD Biosciences). A minimum of 10,000 events
was collected in list mode on FACSDiva software.
To test their suppressive activity, at the end of coculture,
CD4+CD25+ T cells (104/well) were purified, irradiated, and
added to cultures consisting of CFSE-labeled CD3+ T cells
(105/well) as responders, stimulated by allogeneic immature
Mo-DCs (1 : 10). After 5 days, cultures were analyzed using
BD FACSCanto II equipment (BD Biosciences) [25].
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2.8. Generation of Leukemic Lysate and DC Pulsing. AML
cells were resolved in complete medium at 107 cells/mL. Cells
were treated with three cycles of heating (10min at 37∘C)
and freezing (10min at −80∘C) and the necrotic cell material
was filtered throughout a 29G syringe. The cell suspension
was added to immature Mo-DCs (2 : 1). After an overnight
incubation, pulsed DCs were washed and matured with the
cytokine cocktail with or without PGE
2
[26].
2.9. Evaluation of IFN-𝛾 Producing CD3+ T Cells. Leukemia-
reactive IFN-𝛾 producing CD3+ T cells were evaluated after
the coculture with DCs pulsed with leukemic lysate and
matured with the cytokine cocktail containing PGE
2
. After
4 h of incubation, brefeldin A was added (2𝜇g/mL, Sigma-
Aldrich) and incubated overnight at 37∘C. At the end of the
incubation, cell-surface staining was performed as described
above (anti-CD4 FITC: clone OKT4, anti-CD8 APC: clone
HIT8a, Biolegend). Then, cells were fixed (30min at 4∘C in
2% paraformaldehyde (Sigma-Aldrich)) and the anti-IFN-𝛾
antibody (clone B27; Biolegend) was added in 0.1% saponin
and incubated for 30min at 4∘C.
Both assays were performed in the presence or absence
of 1-MT-L (1mM). At the end of the culture time, cultures
were analyzed using BD FACSCanto II equipment (BD
Biosciences).
2.10. Statistical Analysis. Results are expressed as mean ±
SEM. Depending on experimental conditions analysis has
been performed with statistical Student’s 𝑡-test or ANOVA
(post hoc Bonferroni), ∗𝑃 < 0.05, ∗∗𝑃 < 0.01.
3. Results
3.1. PGE2 Enhances IDO1 Expression and Activity. We first
investigated whether different inflammatory stimuli affect
IDO1 expression by Mo-DCs during maturation. To this
end, we evaluated IDO1 expression in human Mo-DCs after
maturation with LPS in presence or absence of IFN-𝛾, or with
a cocktail of cytokines including IL-1𝛽, IL-6, and TNF-𝛼, with
and without PGE
2
. Immature Mo-DCs were used as control
samples. In line with previous reports [20], maturation
of DCs resulted in the significant upregulation of IDO1
(Figure 1(a)). IDO1 was strongly induced by LPS plus IFN-
𝛾 and by the cytokine cocktail containing PGE
2
. In absence
of PGE
2
the cytokine cocktail induced IDO1 at low level
(Figure 1(a)). Of note, in presence of either LPS plus IFN-𝛾
or the cytokine cocktail completed of PGE
2
, DCs expressed
the highest level of CD80, CD86, CD40, CD83, and CCR7,
whereas in presence of the cytokine cocktail without PGE
2
,
DCs expressed the lowest level of thesemarkers (Figure 1(b)).
To test the enzymatic activity of IDO1, supernatants
of immature and mature DCs cultured with tryptophan-
enriched medium were analyzed for L-kynurenine produc-
tion. As shown in Figure 1(c), L-kynurenine production
confirmed, at the functional level, mRNA expression results.
Indeed, L-kynurenine concentration was increased aftermat-
uration, especially in the presence of LPS plus IFN-𝛾 or the
cytokine cocktail containing PGE
2
, whereas in absence of
PGE
2
it was weakly increased. L-kynurenine increase was
inhibited by 1-MT-L, thus suggesting that the L-kynurenine
production was due to IDO1 enzymatic activity.
These findings show that IDO1 expression and function
are strongly modulated by the environmental cytokine com-
position and that PGE
2
, which is required for full maturation,
may also act as a switch for IDO1 expression and function.
3.2. The Inhibition of IDO1 in PGE2-Matured DCs Enhances
T-Cell Proliferation. Once evaluating that PGE
2
may act as a
switch for IDO1 expression, we compared the ability of DCs
matured with and without PGE
2
in inducing T-cell prolif-
eration. We tested whether a high expression of IDO1 (i.e.,
in presence of PGE
2
) by mature DCs resulted in a stronger
inhibition of their ability to stimulate allogeneic or autologous
T-cell proliferation in comparison to a low expression of IDO1
(i.e., in absence of PGE
2
). Therefore, we used DCs matured
with or without PGE
2
as stimulators and allogeneic or autol-
ogous CD3+ T cells as responders. Although PGE
2
has been
shown to confer toDCs some tolerogenic features, such as IL-
10 release [27] and IDO1 expression [20, 21], its combination
with TNF-𝛼, IL-1𝛽, and IL-6 enhances their immunogenicity
by upregulating costimulatory molecules, stimulating the
migration capacity and inducing IL-6 and IL-12 release [28–
30]. Indeed, PGE
2
-matured Mo-DCs showed a stronger
immunostimulatory activity, both in the allogeneic and autol-
ogous setting, thanDCsmaturedwithout PGE
2
(Figure 2(a)).
However, the addition of 1-MT-L resulted in the signifi-
cant enhancement of the proliferative capacity of allogeneic
(Figure 2(b)) and autologous (Figure 2(c)) T-cells, demon-
strating the tolerogenic role of IDO1. Of note, we observed an
increase of T-cell proliferation after addition of 1-MT-L also
when DCs cultured without PGE
2
were used as stimulators.
Since IDO1 expression in DCs generated in absence of PGE2
is under the level of detection, these results may be explained
by an off-target effect of 1-MT-L or by an interference with
other tryptophan metabolic pathways, such as tryptophan
dioxygenase and/or IDO2.
Taken together, these results suggest that while DCs
matured with PGE
2
retain a stronger capacity of stimulating
T-cell proliferation than those matured without PGE
2
, they
also upregulate the expression of the immunosuppressive
enzyme IDO1. While PGE
2
is necessary to enhance stimula-
tory capacity of DCs by inducing a complete maturation, it is
also implicated in the induction of tolerogenic pathways, such
as IDO1. Indeed, the inhibition of IDO1 further enhances the
stimulatory capacity of DCs matured with PGE
2
.
3.3. IDO1-Expressing DCs Strongly Induce T
𝑟𝑒𝑔𝑠
. To investi-
gate the role of PGE
2
in inducing IDO1-mediated Tregs gen-
eration, we cocultured PGE
2
-maturedDCswith purified allo-
geneic or autologous CD3+ T cells. As shown in Figures 3(a)
and 3(b), DCs induced a significant increase of the per-
centage of newly generated allogeneic and autologous
CD4+CD25+Foxp3+ T cells, respectively, as compared to
CD3+ T cells cultured alone. Accordingly, the addition to the
cocultures of 1-MT-L significantly reduced the percentage of
CD4+CD25+Foxp3+ T cells, thus suggesting that IDO1 rep-
resents an important mechanism by which DCs induce
CD4+CD25+Foxp3+ T cells in the presence of PGE
2
. To
4 Journal of Immunology Research
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
Immature LPS CocktailLPS/IFN-𝛾
∗∗
∗∗
∗∗
∗
Cocktail
PGE2w/o
2
−
Δ
Δ
Ct
(a)
0
20
40
60
80
100
HLA-DR CD1a CD86 CD40 CD80 CD83 CCR7
Po
sit
iv
e c
el
ls 
(%
)
Immature
LPS
Cocktail
Cocktail w/o 
LPS/IFN-𝛾
∗
∗ ∗ ∗
∗
∗ ∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
PGE2
(b)
0
5
10
15
20
25
30
35
40
Medium
1-MT-L
Immature LPS Cocktail CocktailLPS/IFN-𝛾
∗∗
∗∗
∗∗
∗∗ ∗∗
∗∗
∗∗
∗∗
Ky
nu
re
ni
ne
 co
nc
en
tr
at
io
n 
(𝜇
M
)
PGE2w/o
(c)
Figure 1: Mature DCs expressed a functionally active IDO1 protein. Human CD14+ cells were isolated from healthy donors’ PBMC by using
magnetic beads. Immature Mo-DCs were obtained after a 5-day culture in presence of GM-CFS and IL-4. Mature Mo-DCs were obtained
following 2 days of incubationwith LPS, LPS plus IFN-𝛾, the cytokine cocktailmade of IL-1𝛽, IL-6, andTNF-𝛼, with orwithout PGE
2
. (a) Cells
were lysed andRNAwas extracted.mRNAexpression of IDO1 (normalized toGAPDH)was evaluated by real-timeRT-PCR.Universal human
RNAwas used as reference and taken as value of 1. Data are expressed as themean± SEMof 7 independent experiments. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01
versus immature DCs. (b) DC phenotype was evaluated by flow cytometry. (c) DCs were cultured in presence of 500𝜇ML-tryptophan for 4 h
and supernatants were collected. IDO1 enzymatic activity was evaluated with a spectrophotometric analysis as the production of kynurenine
in the supernatants. Data are expressed as the mean ± SEM of 5 independent experiments. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 versus immature DCs or
versus medium alone.
validate their Tregs nature, after coculturewith PGE2-matured
Mo-DCs, purified CD4+CD25+ T cells were able to inhibit T-
cell proliferation (Figure 3(c)). Thus, these results show that
the CD4+CD25+ T cells obtained after coculture with IDO1-
expressing DCs may be considered bona fide Tregs.
Taken together, these data support the hypothesis that
DCs matured in presence of PGE
2
acquire the ability of
inducing a large number of newly differentiated and func-
tional Tregs and that such property is linked to the expression
of the immunoregulatory enzyme IDO1.
3.4. IDO1 Inhibition Enhances the DC Capacity to Elicit the
IFN-𝛾 Production of Leukemia-Specific TCells. In the attempt
to reproduce in vitro a model of antileukemia vaccination
and to understand the role of PGE
2
in the induction of
an antileukemic response, immature DCs were loaded with
necrotic AML blasts, thenmatured with the cytokine cocktail
in presence of PGE
2
, and, finally, used as stimulators for autol-
ogous CD3+ T cells. As shown in Figure 4(a),Mo-DCs loaded
with leukemic antigens were highly efficient in stimulating
IFN-𝛾-secreting CD3+ T cells. However, although IDO1 inhi-
bition did not impact on the allostimulatory capacity of Mo-
DCs previously pulsedwith leukemic blasts (data not shown),
the addition of IDO1 inhibitor 1-MT-L resulted in a significant
enhancement of the percentage of IFN-𝛾-secreting CD3+ T
cells. This result suggests that IDO1 expression can inhibit
the generation of leukemia-specific IFN-𝛾-secreting CD3+ T
cells. Moreover, among the CD3+ T cells, only CD4+ T cells
were able to produce IFN-𝛾 if stimulated with DCs matured
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Figure 2: IDO1 expression inhibited the stimulatory capacity of mature DCs. (a) DCs matured with the cytokine cocktail without PGE
2
(expressing low IDO1) or complete of PGE
2
(expressing high IDO1) were used as stimulator of either allogeneic or autologous CD3+ T cells.
For the stimulation of autologous CD3+ T cells, DCs were previously pulsed with tetanus toxin. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01. Both in the allogeneic
(b) and in the autologous (c) setting, the assay was performed either in presence or in absence of the IDO1-specific inhibitor 1-MT-L. The
results are expressed as the mean of fold increase of 5 independent experiments ± SEM. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 versus medium alone.
with PGE
2
. Of note, the inhibition of IDO1 by 1-MT-
L resulted in a significant enhancement of both IFN-𝛾-
secreting CD4+ and CD8+ T cells. Overall, these findings
show that the expression of IDO1 inDCsmatured in presence
of PGE
2
is able to inhibit the generation of both leukemia-
reactive IFN-𝛾-secreting CD4+ and CD8+ T cells.
3.5. PGE2 Strongly Upregulates IDO1 Expression in DCs from
AML Patients. To better elucidate the effects of PGE
2
in
the setting of dendritic cell vaccination after chemotherapy-
induced remission in acute myeloid leukemia, we evaluated
IDO1 expression in normalMo-DCs obtained from leukemia
patients in complete remission. Also in this setting, Mo-DCs
were matured in presence of the cytokine cocktail with or
without PGE
2
. As expected, in presence of PGE
2
we found,
at mRNA level, a significant upregulation of IDO1 expression
(Figure 5). Accordingly with the results obtained with Mo-
DCs of healthy donors, we observed the highest expression of
costimulationmarkers in presence of PGE
2
(data not shown).
These findings confirm that PGE
2
is a potent inducer of
IDO1 expression in DCs from leukemia patients similarly to
DCs from healthy donors and might result in the induction
of some of the tolerogenic effects observed in DC vaccination
which are mediated by the immunosuppressive enzyme
IDO1.
4. Discussion
Increasing evidence that DC vaccines can induce tumor-
specific immune responses in cancer patients is newly leading
for the development of therapeuticDC-based cancer vaccines
[16, 31, 32]. In this view, it has been shown that type-1 polar-
ized DCs drive Th1-type immune responses that have the
potential to mediate tumor therapy through multiple effec-
tors, such as CD8+ CTLs andTh1-skewed CD4+ T helper cells
[33, 34]. Moreover, tumor cell loaded type-1 polarized DCs
induceTh1-mediated tumor immunity [35].
6 Journal of Immunology Research
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Figure 3: IDO1 expression induced Tregs. Expression of Foxp3 on (a) allogeneic and (b) autologous CD4
+CD25+ T after 5-day culture with
or without high IDO-expressing DCs that is matured with IL-1𝛽/IL-6/TNF-𝛼/PGE
2
(complete cocktail), in presence or in absence of the
IDO1-specific inhibitor 1-MT-L. The results showed in (a)-(b) are expressed as the mean ± SEM of 5 different experiments. ∗∗𝑃 < 0.01. (c)
CD3+ T cells were stimulated by allogeneic immature DCs in the presence and absence of CD4+CD25+ T cells. CD4+CD25+ T cells were
purified after 5 days of culture in presence of high IDO-expressing DCs (i.e., matured with PGE
2
). The results are expressed as percentage of
CD3+ T cell proliferation with the proliferation observed in absence of CD4+CD25+ T cells (w/o Tregs) as 100%. The results are expressed as
the mean ± SEM of 3 different experiments. ∗∗𝑃 < 0.01 versus w/o Tregs.
In preclinical studies, type-1 polarized DCs are gener-
ated, from peripheral blood-derived precursors, by various
cocktails of cytokines, commonly including IL-1𝛽, TNF-𝛼,
IL-6, PGE
2
, and/or IFN-𝛾 [18]. However, these cocktails of
cytokines induce one of the main emerging mechanisms of
immunosuppression, IDO1 (present report, [20, 36]), whose
expression has been demonstrated to have implications for
DC-based vaccines [22]. Notably, the impact on IDO1 expres-
sion of the different cytokines which are used for the formu-
lation of DCs-based vaccines is not fully elucidated [37]. In
particular the role on IDO1 expression of PGE
2
, which is
the most powerful maturation stimulus [38], needs further
investigation.
In the present work we firstly compare different matu-
ration stimuli in order to evaluate their capacity in induc-
ing IDO1 and thus in generating tolerogenic Mo-DCs. In
agreement with von Bubnoff and colleagues [39], we show
that, duringmaturation, IDO1 expression is enhanced inMo-
DCs. Such result indicates that alongside the induction of full
maturation of DCs, inflammatory cytokines and in particular
PGE
2
upregulate IDO1. It has been already demonstrated that
PGE
2
modulates IDO1 expression in circulating DCs from
healthy subjects, playing a role in the induction of one of the
most important mechanisms of immune tolerance, through
the generation of regulatory T cells [38]. Nevertheless, PGE
2
is known to enhance the ability of DCs to migrate towards
the lymph-nodes, as a consequence of upregulation of CCR7
[40]. Furthermore, it has been shown that DCs matured in
presence of PGE
2
retain full ability in inducing allogeneic T-
cell proliferation and in stimulating antigen-specific immune
responses [28, 29]. In agreement, our data indicate that the
presence of PGE
2
results in an enhanced antigen presenting
capacity of DCs. However, our data indicate that PGE
2
medi-
ates also tolerogenic effect through the induction of IDO1 in
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Figure 4: IDO1 expression inhibited leukemia-specific IFN-𝛾 production. AML cells were lysed and used for the pulsing of immature Mo-
DCs. Mo-DCs were subsequently matured with the cytokine cocktail containing PGE
2
. Autologous CD3+ T cells were cocultured with the
preloaded andmatured DCs for an overnight, in the presence or absence of the IDO1-specific inhibitor 1-MT-L. As control samples, unloaded
Mo-DCs were used (data not shown). (a) CD3+ T cells, (b) CD4+ T cells, and (c) CD8+ T cells were tested for leukemia-specific intracellular
IFN-𝛾 production. Results are expressed as the mean ± SEM of 3 independent experiments. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 versus w/o DCs or versus
medium alone.
Mo-DCs. Indeed, the inhibition of IDO1 with its inhibitor 1-
MT-L highly increased the response to tetanus toxin elicited
by DCs matured with PGE
2
. Thus, IDO1 expression by
humanDCs can result in the inhibition of T-cell proliferation
(present report and [36]). Furthermore here we show that
the addition to the culture of 1-MT-L significantly reduce
the percentage of newly generated allogeneic and autologous
CD4+CD25+Foxp3+ Tregs, corroborating the hypothesis that
IDO1 overexpression affects the efficiency of the antitumor
response. Thus, in the perspective of the development of a
DC-based anticancer vaccine, the use of PGE
2
appears to
be essential in order to generate fully mature DCs, but it is
also necessary to minimize tolerogenic effects, such as the
upregulation of the immunosuppressive enzyme IDO1.
A DCs-based vaccine against leukemia may be a suc-
cessful strategy for the control or the eradication of the
minimal residual disease.We previously demonstrated that in
leukemic DCs, generated from acute myeloid leukemia cells,
maturation with the complete cocktail of cytokines induces
the upregulation of IDO1 gene and protein, thus resulting in
tolerogenic effects that have important implications for the
use of these cells as vaccines [26]. In the present work, we find
that also normalMo-DCs, obtained fromAMLpatients, show
high level of IDO1 expression after maturation with PGE
2
-
containing cytokine cocktail. Accordingly, blocking IDO1
activity by 1-MT-L in AML-loaded DCs, matured in presence
of PGE
2
(and consequently expressing high level of IDO1),
strongly enhanced the leukemia-specific IFN-𝛾 production
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Figure 5: IDO1 expression is enhanced in Mo-DCs from AML
patients matured with PGE
2
. HumanCD14+ cells were isolated from
PBMC of AML patients in complete remission by using magnetic
beads. Immature Mo-DCs were obtained after a 5-day culture in
presence of GM-CSF and IL-4. Mature Mo-DCs were obtained
following 2 days of incubation with the cytokine cocktail made of
IL-1𝛽, IL-6, and TNF-𝛼, with or without PGE
2
. Cells were lysed
and RNA was extracted. mRNA expression of IDO1 (normalized
to GAPDH) was evaluated by real-time RT-PCR. Universal human
RNA was used as reference and taken as value of 1. Results are
expressed as fold increase of gene expression over immature Mo-
DCs (taken as referral condition). The results represent the mean
of 3 independent experiments ± SEM. ∗∗𝑃 < 0.01 versus immature
DCs.
by T-cells. Our results indicate that an IDO1-mediated immu-
nosuppressive mechanism is involved in weakening the anti-
tumor efficacy elicited by AML-loaded DCs and that specific
inhibition of IDO1 might be required for development of
cancer vaccines. Our conclusion is in linewith recent findings
showing that 1-MT enhances the potency of DC-based vac-
cine against pancreatic adenocarcinoma and Lewis lung car-
cinoma (LLC) [41, 42]. In fact, in mice, the administration of
1-MT plus DC vaccine caused a slower increase of pancreatic
adenocarcinoma as compared to the treatment with either
DC or 1-MT alone. In addition, 1-MT enhances the antitumor
efficacy elicited by DC/LLC fusion vaccine by delaying the
tumor development and inducing stronger splenic CTL
responses. Currently, different strategies are under investiga-
tion to improve the clinical efficacy of DC-based vaccines for
cancer [43, 44]. The use of small interfering RNA to knock
down IDO1 expression in a mouse model of breast cancer
resulted in the enhancement of the immunogenicity of a DC-
based vaccine [45]. Encouraging results were also obtained
in cancer patients through immunization with IDO-silenced
DCs [46].
5. Conclusions
Our paper demonstrates that by combining PGE
2
with 1-
MT-L, it is possible to obtain fully mature Mo-DCs that
weakly induce Tregs and that elicit IFN-𝛾 release by T cells
stimulated with AML antigens. Since selective IDO1 inhibitor
compounds are currently under clinical investigation, phar-
macological IDO1 inhibition is becoming an innovative
strategy to potentiate the antitumor efficacy of DC-based
vaccines.
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